

Journal für

Reproduktionsmedizin und Endokrinologie

– Journal of Reproductive Medicine and Endocrinology –

Andrologie • Embryologie & Biologie • Endokrinologie • Ethik & Recht • Genetik
Gynäkologie • Kontrazeption • Psychosomatik • Reproduktionsmedizin • Urologie



New Technologies for Intrauterine Contraception and Treatment: Design that Fits

Wildemeersch D

J. Reproduktionsmed. Endokrinol 2011; 8 (Sonderheft
1), 222-226

www.kup.at/repromedizin

Online-Datenbank mit Autoren- und Stichwortsuche

Offizielles Organ: AGRBM, BRZ, DVR, DGA, DGGEF, DGRM, D-I-R, EFA, OEGRM, SRBM/DGE

Indexed in EMBASE/Excerpta Medica/Scopus

Krause & Pachernegg GmbH, Verlag für Medizin und Wirtschaft, A-3003 Gablitz



ENDO FERTI FORUM

ENDOKRINOLOGIE & FERTILITÄT
FÜR KLINIK & PRAXIS

20.-21. März 2026

Universitätsmedizin Mainz

Einladung zu unserer wissenschaftlichen Veranstaltung Endo-Ferti-Forum

Brücke(n) zwischen Unikliniken und Praxen an Rhein und Main(z)

– die aus dem bisherigen Format „Ferti Forum“ ab 2026 hervorgeht –



Freuen Sie sich auf spannende Vorträge und den lebendigen Austausch mit Kolleg:innen und Expert:innen aus Klinik und Praxis. Freitagabend laden wir Sie herzlich zu einem entspannten Empfang ein – eine perfekte Gelegenheit, Kontakte zu knüpfen und den Tag genussvoll ausklingen zu lassen.

Wissenschaftliche Leitung: Univ.-Professorin Annette Hasenburg, Dr. Susanne Theis, Universitätsmedizin Mainz, Sanitätsrat Dr. Werner Harlfinger, BVF Rheinland-Pfalz Dr. Rüdiger Gaase, BVF Hessen Dr. Klaus J. Doubek

Schirmherrschaften: Prof. Nicole Sänger, Uniklinik Bonn, Prof. Jan-Steffen Krüssel, Uniklinik Düsseldorf, Dr. Annette Bachmann, Uniklinik Frankfurt am Main, Prof. Christine Skala, Uniklinik Köln

Weitere Informationen
& Anmeldung unter



New Technologies for Intrauterine Contraception and Treatment: Design that Fits

D. Wildemeersch

A strategic advantage of intrauterine devices and systems is that, unlike the Pill, they are genuinely 'fit-and-forget'. In use, they are more effective than Pills, particularly in adolescents and nulliparous women, as they have a relatively high continuation of use. The World Health Organization concluded that IUDs can be used and that they are safe for young women, including adolescents. Because adolescents and young nulliparous women contribute disproportionately to the epidemic of unintended pregnancies, suitable long-acting methods of contraception, such as the IUD or IUS, should be advocated as first-line choices for interval, emergency and immediate post-abortion contraception in this population of women.

However, a major drawback is that they do not fit in uterine cavities of many women. Uterine cavities of nulliparous women are usually smaller than those of parous women. As current copper IUDs and the, at present, only available LNG-IUS may not be suitable for many young women, new developments in intrauterine technology, smaller frameless and framed copper and hormone-releasing devices, could help increase the prevalence of use, particularly continued use of this method in women, including in adolescents and nulliparous women, and help reduce the number of unintended pregnancies and induced abortions. **J Reproduktionsmed Endokrinol 2011; 8 (Special Issue 1): 222–6.**

Key words: frameless and framed copper IUD, levonorgestrel IUS, contraception, unintended pregnancy, adolescents, nulliparous women

■ Introduction: One Design does not fit all Uterine Cavities

Intrauterine devices and intrauterine systems, apart from being long-acting, are particularly attractive as they possess all characteristics listed in Table 1. Moreover, they act locally, avoiding potentially serious systemic adverse effects. A recent re-assessment of the risk of pelvic inflammatory disease attributable to an intrauterine device concluded that intrauterine devices do not affect the fertility of adolescents [2]. Fecundity also rapidly returns to normal after IUD removal [3, 4]. In addition, the levonorgestrel-releasing intrauterine system may offer some protection against sexually transmitted infection [5].

However, uterine cavities differ considerably in size and shape, and the uterus is subject to changes in size and volume

during the menstrual cycle [6, 7]. These changes are most pronounced at the time of menses. These individual variations in size and shape of the human uterus are probably greater than variations of the human foot (H.M. Hasson). Therefore, it would be unreasonable to expect one standard-sized IUD/IUS to fit in uterine cavities that differ in size and volume from woman to woman and from time to time in the same woman. Clinical experience has shown that dimensional incompatibility between the IUD/IUS and the uterine cavity can lead to partial or total expulsion, perforation of the uterine wall, pain, unintended pregnancy, and abnormal or heavy uterine bleeding leading to removal of the device [8–10].

Research has shown that if the width of the uterine cavity is too small, side effects and complications are likely to occur. The crossarms of standard T-shaped IUDs are frequently too long for a large

number of uterine cavities, as the average transverse diameter of the uterine cavity in the majority of women is smaller than the span of the crossarms of the IUD (Fig. 1). The average transverse diameter of the uterine cavity at the fundal level in nulliparous women between 15 and 34 years of age, as well as in many parous women, is much smaller than the length of the crossarms of most currently used T-shaped IUDs resulting in dimensional problems. The length of the crossarms of the TCU380A IUD and the Mirena® LNG-IUS is 32 mm. The average fundal transverse dimension in nulliparous as well as parous women is only around 25 mm.

Recent 3-D sonography studies compared women with abnormally and those with normally located IUDs with respect to their indication for sonography and found that the proportion of patients whose principal indication for sonogra-

Table 1. Advantages of the IUD/IUS Methods

1. They do not depend on coitus and user motivation and adherence
2. They have the highest effectiveness, continuation rates and satisfaction [1]
3. They do not require frequent visits for resupply
4. They require no additional funding for consistent use once they have been placed
5. They are highly cost-effective
6. They are reversible, with rapid return of fertility after removal




Figure 1. Examples of severe disproportion caused by too long crossarms of copper IUDs (a, b) (courtesy of Dr. A. de Castro and Dr. K.-H. Kurz) and of the Mirena® LNG-IUS (3-D sonography) (c) (courtesy of Dr. D. Van Schoubroeck).

Received and accepted: April 18, 2011

Correspondence: Dr. Dirk Wildemeersch, MD, PhD, Outpatient Gynecological Clinic and IUD Training Center, F. Rooseveltlaan 44, 9000 Ghent, Belgium; e-mail: d.wildemeersch@skynet.be






Figure 2. Other examples of severe disproportion caused by too long crossarms of copper IUDs (courtesy of Dr. B. Benacerraf, with permission). These pictures show coronal views of the uterine cavities of three different patients (a–c) with intrauterine contraceptive devices abnormally located in different parts of the myometrium or cervix.



Figures 3. The figures above show the GyneFix® 330 IUD (a), the small frameless GyneFix® 200 IUD (b) and the FibroPlant® LNG-IUS (c), inserted in a foam uterus. The frameless copper IUD consists of a number of copper tubes attached to an anchoring thread with anchoring knot on top. The drug delivery fiber (1.6 mm in diameter) of the frameless LNG-IUS is attached to the anchoring thread with a stainless steel clip, one cm below the anchoring knot. The latter is inserted in the myometrium of the uterine fundus with a specially designed inserter.



Figures 4. 3-D ultrasound of GyneFix®, illustrating the compatibility of the frameless IUD with the uterine cavity of a parous woman (a) (courtesy of Dr. med. P. Villars) and a very narrow uterine cavity (19.1 mm) in a young nulliparous woman (b) (courtesy of Dr. S. Jandi) and the frameless FibroPlant® LNG-IUS (c) (courtesy of Dr. D. Van Schoubroeck).

phy was bleeding, pain or bleeding and pain were significantly greater in those with an abnormally located IUD, including imbedded IUDs, compared with those whose IUD was not located abnormally on 3-D sonography [11, 12]. It should be noted that standard 2-D sonography is not able to detect many abnormally located IUDs particularly with regard to abnormal location of the sidearms of the IUD. Accurate location of the sidearms is only possible by hysteroscopy and with 3-D coronal sonography, as shown in Figure 2.

A study in current and former Copper T IUD users found a dissatisfaction rate of 34% [13]. The reason for the discontinuation in this study was not available but previous studies showed that heavy bleeding and pelvic pain were the most commonly cited reasons for discontinuing copper IUDs [14–16]. It is therefore logical, as has been confirmed in clinical trials, that harmony between the size of the foreign body and the dimensions of the uterine cavity is essential as regards its acceptability, the occurrence of side effects and the continued use of the

method [17–21]. Expulsion rates exceeding 10% during the first year of use have been reported in adolescent nulliparae using traditional IUDs [22, 23]. Recently, a study with the Mirena® conducted in adolescent women in New Zealand found an expulsion rate of 8% after one year of use [24]. The most important factor in reducing IUD side effects, including expulsion, is the elimination of distortion of the uterine cavity (Howard Tatum, inventor of the T-shaped IUD) [25].

■ The Advantage of Intra-uterine Methods that Fit

The frameless copper-releasing GyneFix® IUDs and the frameless FibroPlant® LNG-IUS were developed to optimize harmony with the uterine cavity of parous and nulliparous women in an attempt to reduce the side effects and expulsion rates of conventional IUDs, and consequently, increase continuation of use (Fig. 3).

Figure 4 illustrates the position of the frameless and flexible IUD/IUS in uterine cavities which differ in size and shape as well as the absence of dimensional incompatibility even if the fundal transverse diameter is extremely small.

Different versions of GyneFix® have been clinically tested in large multi-center randomized and non-randomized clinical trials. The high effectiveness has been demonstrated in a randomized comparative study conducted by the WHO and others [26–28]. Failures range from 0.0/100 users to 2.5/100 users (cumulative rates) during the first year up to 10 years of use in published randomized and non-randomized comparative clinical trials [29]. The smaller GyneFix® version has a similar high efficacy [30]. In addition, clinical trials demonstrated, for the first time, the absence of a significant effect of the tiny IUD on menstrual blood loss (Tab. 2) due to the very small size and optimal harmony with the uterine cavity, leaving the cavity totally undisturbed [31]. This is important since abnormal bleeding and pain are the two major reasons for IUD discontinuation [32]. Kivijarvi et al. found clinical anemia in 10% of users of copper IUDs after 12 months exposure and iron deficiency, as judged by the ferritin levels, could be demonstrated

Table 2: Menstrual blood loss evaluation in users of the small GyneFix® 200 IUD. Characteristics of the study group (n = 60, 23 parous and 37 nulliparous women) and analysis by the pictorial bleeding assessment technique, measuring the difference in menstrual score (MS) before and during use of the GyneFix® 200 IUD.

	Age	MS at insertion	MS at last follow-up
n = 60			
Mean	30.4	116.7	115.2
SD	8.5	52.9	51.1
Median	30.5	110.5	110.0
Range	17–46	28–265	28–260

Wilcoxon matched-pairs signed-ranks test: p = 0.596 (n. s.).

in 20% [33]. In a Swedish study in CuT380A IUD users an increase in MBL was shown which ranged between 50 and 60% [34]. This study is comparable with previous reports regarding the increase in MBL associated with the use of a copper IUD. Attempts to reduce menstrual bleeding in TCu380A users with the use of nonsteroidal anti-inflammatory drugs for analgesia yielded mixed results [35]. Anti-inflammatory drugs were also unsuccessful in reducing the removal rate due to cramping pain [36].

As a consequence of the harmonious relationship of the frameless GyneFix® IUD with uterine cavities with a different transverse diameter, removal rates for abnormal bleeding and pain complaints have been low (< 1/100 women per year at 3 years), particularly with the smaller version. Consequently, high continuation rates were recorded (over 90% at 3 years) which continued to be high during the years thereafter. Contraceptive discontinuation rates of conventional IUDs and the Mirena® LNG-IUS are known to be higher among adolescents than for adult women. The Mirena® discontinuation rates in females aged 18–25 years was 20% at one year, with pain as the leading cause for removal [37]. This corresponds with an IUD/IUS study conducted in nulliparous women in the UK [38]. Earlier studies also reported LNG-IUS discontinuation rates because of pain and bleeding problems that are higher in the younger age groups [39, 40]. Similarly, heavy menses and dysmenorrhea are the most frequent reasons for the removal of the TCu380A in the first year after insertion [41].

The length of the IUD does not seem to be important clinically, unless there is a great difference between cavity length

and the length of the stem of the IUD/IUS. It appears, therefore, that the main factor related to dimensional or spatial compatibility of the IUD/IUS with the uterine cavity remains the width or transverse diameter of the uterine cavity. 3-D sonography provides useful information on the location of the IUD/IUS and enables proper imaging of the device and the relationship between the IUD/IUS and the uterine cavity. Visualizing the acoustic shadow of the IUD/IUS provides a useful additional modality in cases of difficult visualization [42, 43].

■ There is No Increased Risk of Perforation with the Frameless, Anchored IUD/IUS

Of the 5346 insertions (4808 interval and 543 immediately post-abortion) conducted in clinical trials with the frameless copper-releasing IUD, there were no perforations [26]. In the two large post-marketing trials conducted in Belgium and Spain with GyneFix® in over 12,000 women, the rate was 1.2–2.0/1000 insertions which is similar to the quoted perforation rate occurring with traditional IUDs [44]. The risk of perforation can be reduced by proper training (see below) and by visualization of the anchor by ultrasound. The manufacturer of the frameless GyneFix® and frameless FibroPlant® LNG-IUS incorporated a small metal particle in the anchoring system rendering the anchor highly visible on ultrasound examination (Figs. 5, 6) (patent pending). This allows assessment of the proper position of the anchor in the muscle of the uterine fundus following insertion and at follow-up. In the rare event of perforation of the uterine serosa, or in case of doubt, the frameless




Figure 5: 2-D sonography of the new "visualized" anchor (See arrow). The anchor is located 6 mm from the serosa of the uterus.




Figure 6: 3-D sonography of the new "visualized" anchor (See arrow).




Figure 7: Home Uterine Trainer (HUT®) suitable for home-training of the frameless IUD/IUS insertion technique.

IUD/IUS can be removed and a new insertion can be performed immediately or at a later date.

■ Training Aspects

As the frameless technology is new, familiarity with the insertion procedure may be acquired only after a number of insertions have been completed, depending on the skill of the provider. Experience has shown that insertion failures and expulsions, in parous as well as nul-

liparous women, can be minimized to very low rates if providers attend a training course organized by the manufacturer. Proper training is essential to properly insert the GyneFix® and will result in optimal performance and high continuation of use. Following training, providers can become proficient by conducting training by themselves in an appropriate “home” uterine model (Fig. 7) before they start insertions in their patients.

■ Conclusion

Many unintended pregnancies and induced abortions can be avoided by providing intrauterine devices that cause a high continuation of use. Nulliparous women who need or want a non-systemic contraceptive option may benefit from a smaller framed IUD/IUS or from the frameless copper or a frameless

LNG-releasing system. Among nulliparous women, where the issue of incompatibility may be more pronounced, clinical studies suggest the high tolerance and high continuation rates of the frameless IUD and IUS [29, 45]. In addition, if properly inserted, expulsion of the IUD/IUS is rare.

Young men and women are a highly vulnerable population. They deserve to be informed and to have access to high-quality and effective reproductive health care assistance. High-performing, forgettable, long-acting, reversible, and well-tolerated contraceptives, with a high continuation of use are needed to reduce unintended pregnancies in young women [46].

However, outdated perceptions about appropriate patient candidate for long-acting methods among health care pro-

viders continue to negatively impact their use. These myths should be vigorously dispelled.

Finally, the gynecological examination, and insertion of an IUD, in young nulliparous women and adolescents, may be challenging. IUD fitting should be done with extreme care and with attention to comfort and pain relief as pain scores may be quite high with vagal reactions [34, 47]. The use of misoprostol may be useful to maximize comfort and facilitate IUD insertion by softening the cervix and reducing the chance of complications such as perforation, pain and bleeding [48].

■ Acknowledgment

Dr. D. Wildemeersch is grateful to a large number of colleagues in Belgium and abroad for being investigators and

co-investigators in the clinical studies conducted with the frameless and framed IUDs/IUSs.

Conflict of Interest

Dirk Wildemeersch, MD, PhD, is a Belgian gynaecologist and Medical Director of Control Drug Delivery Research, an organization which was established to manage clinical research and to develop and study innovative drug delivery technologies, aimed at finding improved methods for prevention and treatment of gynecological conditions, improvements to birth control methods, and higher levels of safety, user acceptability, compliance and quality of life for women. Control is the manufacturer of GyneFix®, FibroPlant® and Femilis®. The research organization also provides insertion training for doctors. The funds generated are used for conducting further research and to participate in humanitarian projects.

References:

- Trussell J. Contraceptive failure in the United States. *Contraception* 2011; 83: 397–404.
- Hubacher D, Lara-Ricalde R, Taylor DJ, Guerra-Infante F, Guzman-Rodriguez R. Use of copper intrauterine devices and the risk of tubal infertility among nulligravid women. *N Engl J Med* 2001; 345: 561–7.
- Penney G, Brechin S, de Souza A, Bankowska U, Belfield T, Gormley M, et al. FFRHC Guidance (January 2004). The copper intrauterine device as long-term contraception. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit [published erratum appears in *J Fam Plann Reprod Health Care* 2004; 30: 134]. *J Fam Plann Reprod Health Care* 2004; 30: 29–41.
- Hov GG, Skjeldstad FE, Hilstad T. Use of IUD and subsequent fertility – follow-up after participation in a randomized clinical trial. *Contraception* 2007; 75: 88–92.
- Toivonen J, Luukkainen T, Allonen H. Protective effect of intrauterine release of levonorgestrel on pelvic infection: three years' comparative experience of levonorgestrel- and copper-releasing intrauterine devices. *Obstet Gynecol* 1991; 77: 960–1.
- Hasson HM. Clinical studies of the Wing Sound II metrology device. In: Zatuchni GI, Goldsmith A, Sciarra JJ (eds). *Intrauterine Contraception: Advances and Future Prospects*. Harper & Row, Philadelphia, 1984; 126–41.
- Kurz KH. Cavimeter uterine measurements and IUD clinical correlation. In: Zatuchni GI, Goldsmith A, Sciarra JJ (eds). *Intrauterine Contraception: Advances and Future Prospects*. Harper & Row, Philadelphia, 1984; 142–62.
- Kamal I, Hefnawi F, Ghonheim M, Talant M, Abdalla M. Dimensional and architectural disproportion between the intrauterine device and the uterine cavity: A cause of bleeding. *Fert Steril* 1971; 22: 514–21.
- Roy S, Cooper D, Mishell DR. Experience with three different models of the Copper T intrauterine contraceptive device in nulliparous women. *Am J Obstet Gynecol* 1974; 119: 414–7.
- Petersen KR, Brooks L, Jacobson B, Skouby SO. Intrauterine devices in nulliparous women. *Proceedings 1st Congress of the European Society of Contraception*, Paris, 1990.
- Benacerraf BR, Shipp TD, Bromly B. Three-dimensional ultrasound detection of abnormally located intrauterine contraceptive devices which are the source of pelvic pain and abnormal bleeding. *Ultrasound Obstet Gynecol* 2009; 34: 110–5.
- Shipp TD, Bromly B, Benacerraf BR. The width of the uterine cavity is narrower in patients with an embedded intrauterine device (IUD) compared to a normally positioned IUD. *J Ultrasound Med* 2010; 29: 1453–6.
- Moreau C, Cleland K, Trussell J. Contraceptive discontinuation attributed to method dissatisfaction in the United States. *Contraception* 2007; 76: 267–72.
- World Health Organization. Long-term reversible contraception. Twelve years of experience with TCu380A and TCu220C. *Contraception* 1997; 56: 341–52.
- Speroff L, Darney P. *A Clinical Guide for Contraception*. 2nd ed. Williams & Wilkins, Baltimore (Md), 1996.
- Stanback J, Grimes D. Can intrauterine device removals for bleeding or pain be predicted at one-month follow-up visit? A multivariate analysis. *Contraception* 1998; 58: 357–60.
- Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. *Contraception* 1999; 60: 155–60.
- Toma A, Jamieson MA. Revisiting the intrauterine contraceptive device in adolescents. *J Pediatr Adolesc Gynecol* 2006; 19: 291–6.
- Lacy J. Clinic opinions regarding IUD use in adolescents. *J Pediatr Adolesc Gynecol* 2006; 19: 301–3.
- Hubacher D. Copper intrauterine device use by nulliparous women: review of side effects. *Contraception* 2007; 75: S8–S11.
- Wildemeersch D. Commentary. Intrauterine contraceptives that do not fit well contribute to early discontinuation. *Eur J Contracept Reprod Health Care* 2011; 16: 1–7.
- Weiner E, Berg A, Johansson I. Copper intrauterine contraceptive devices in adolescent nulliparae. *Br J Obstet Gynaecol* 1978; 85: 204–6.
- Liedholm P, Sjöberg NO. Two years experience with Copper-T-200 in a Swedish population – comparison between nulliparous and parous women. *Contraception* 1974; 10: 55–61.
- Paterson H, Ashtin J, Harisson-Woolrych. A nationwide cohort study of the use of the levonorgestrel intrauterine device in New Zealand adolescents. *Contraception* 2009; 79: 433–8.
- Tatum H. Comments made during the 4th Congress of the European Society of Contraception, Barcelona, 12–15 June, 1996.
- Meirik O, Rowe PJ, Peregoudov A, Piaggio G, Petzold M for the IUD Research Group at the UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction. The frameless copper IUD (GyneFix) and the TCu380A IUD: results of an 8-year multicenter randomized comparative trial. *Contraception* 2009; 80: 133–41.
- Wildemeersch D, Andrade A. Commentary. *Contraception* 2009; 80: 133–41.
- Wu S, Hu J, Wildemeersch D. Performance of the frameless GyneFix and the TCu380A IUDs in a three-year multicenter randomized comparative trial in parous women. *Contraception* 2000; 61: 91–9.
- Wildemeersch D, Batár I, Affandi B, Andrade ATL, Wu S, Hu J, Cao X. The 'frameless' intrauterine system for long-term, reversible contraception: A review of 15 years of clinical experience. *J Obstet Gynaecol Res* 2003; 29: 160–9.
- Cao X, Zhang W, Zhao X, Lin N, Wang L, Li C, Song L, Zhang W, Zhang Z, Wildemeersch D. Three-year efficacy and acceptability of the GyneFix® 200 intrauterine system (IUS). *Contraception* 2004; 69: 207–11.
- Wildemeersch D, Rowe PJ. Assessment of menstrual blood loss in Belgian users of the frameless copper-releasing IUD with copper surface area of 200 mm² and users of a copper-levonorgestrel-releasing intrauterine system. *Contraception* 2004; 70: 169–72.
- Wildemeersch D, Rowe PJ. Assessment of menstrual blood loss in women with idiopathic menorrhagia using the frameless levonorgestrel-releasing intrauterine system. *Contraception* 2004; 70: 165–8.
- Kivijarvi A, Timoneb H, Rajamaki A, Gronroos M. Iron deficiency in women using copper intrauterine devices. *Obstet Gynecol* 1986; 67: 95–8.
- Milsom I, Andersson K, Jonasson K, Lindstedt G, Rybo G. The influence of the Gyne-T 380s IUD on menstrual blood loss and iron status. *Contraception* 1995; 52: 175–9.
- Grimes DA, Hubacher D, Lopez LM, Schulz KF. Nonsteroidal anti-inflammatory drugs for heavy bleeding or pain associated with intrauterine-device use. *Cochrane Database of Systematic Reviews* 2006, Issue 4. Art. No.: CD006034. DOI: 10.1002/14651858.CD006034.pub2.
- Hubacher D, Reyes V, Lillo S, Pierre-Louis B, Zepeda A, Chen P-L, Croxatto H. Preventing copper intrauterine device removals due to side effects among first-time users: randomized trial to study the effect of prophylactic ibuprofen. *Human Reprod* 2006; 21: 1467–72.
- Suhonen S, Haukkamaa M, Jakobsson T, Rauramo I. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study. *Contraception* 2004; 69: 407–12.
- Brockmeyer A, Kishen M, Webb A. Experience of IUD/IUS insertions and clinical performance in young nulliparous women – a pilot study. *Eur J Contracept Reprod Health Care* 2008; 13: 248–54.
- Andersson K, Odland V, Rybo G. Levonorgestrel releasing and copper releasing (Nova T) IUDs during five years of use. A randomized comparative study. *Contraception* 1994; 49: 56–72.
- Luukkainen T, Allonen H, Haukkamaa M, Holma P, Pyörälä T, Terho J, Toivonen J, Batar I, Lampe L, Andersson K. Effective contraception with the levonorgestrel-releasing intrauterine device: 12-month report of a European multicenter study. *Contraception* 1987; 36: 160–79.
- Rivera R, Chen-Mok M, McMullen S. Analysis of client characteristics that may affect early discontinuation of the TCu-380A IUD. *Contraception* 1999; 60: 155–60.
- Zohav E, Y Anteby E, Orvieto R. Use of three-dimensional ultrasound in evaluating the intrauterine position of a levonorgestrel-releasing intrauterine system. *RBM Online* 2007; 14: 495–7.
- Valsky DV, Cohen SM, Hochner-Celnikier D. The shadow of the intrauterine device. *J Ultrasound in Medicine* 2006; 25: 613–6.
- Tatum HJ, Connell EB. Intrauterine devices. In: Filshie M, Guillebaud J (eds). *Contraception: Science and Practice*. Butterworths, London, 1989; 144–71.
- Wildemeersch D, Andrade A. Review of clinical experience with the frameless LNG-IUS for contraception and treatment of heavy menstrual bleeding. *Gynecol Endocrinol* 2010; 26: 383–9.
- Grimes DA. Forgettable contraception. *Contraception* 2009; 80: 497–9.
- Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. What methods of analgesia or cervical anaesthesia have been used successfully for insertion of an intrauterine device (IUD or system (IUS)? Enquiry Reference: 2697 (Sent: 25.6.09).
- Saav I, Aronsson A, Marions L, Stephansson O, Gemzell-Danielsson K. Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: A randomized controlled trial. *Human Reproduction* 2007; 22: 2647–52.

Mitteilungen aus der Redaktion

Besuchen Sie unsere Rubrik

☒ Medizintechnik-Produkte



Neues CRT-D Implantat
Intica 7 HF-T QP von Biotronik



Artis pheno
Siemens Healthcare Diagnostics GmbH



Philips Azurion:
Innovative Bildgebungslösung

Aspirator 3
Labotect GmbH



InControl 1050
Labotect GmbH

e-Journal-Abo

Beziehen Sie die elektronischen Ausgaben dieser Zeitschrift hier.

Die Lieferung umfasst 4–5 Ausgaben pro Jahr zzgl. allfälliger Sonderhefte.

Unsere e-Journale stehen als PDF-Datei zur Verfügung und sind auf den meisten der marktüblichen e-Book-Readern, Tablets sowie auf iPad funktionsfähig.

☒ Bestellung e-Journal-Abo

Haftungsausschluss

Die in unseren Webseiten publizierten Informationen richten sich **ausschließlich an geprüfte und autorisierte medizinische Berufsgruppen** und entbinden nicht von der ärztlichen Sorgfaltspflicht sowie von einer ausführlichen Patientenaufklärung über therapeutische Optionen und deren Wirkungen bzw. Nebenwirkungen. Die entsprechenden Angaben werden von den Autoren mit der größten Sorgfalt recherchiert und zusammengestellt. Die angegebenen Dosierungen sind im Einzelfall anhand der Fachinformationen zu überprüfen. Weder die Autoren, noch die tragenden Gesellschaften noch der Verlag übernehmen irgendwelche Haftungsansprüche.

Bitte beachten Sie auch diese Seiten:

Impressum

Disclaimers & Copyright

Datenschutzerklärung